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Abstract: Background: The risk of pulmonary embolism (PE) has not been studied in older patients
affected by COVID-19. We aimed to assess PE incidence and risk factors in a population of older
patients infected with SARS-CoV-2. Methods: An ambispective, observational cohort study. A total
of 305 patients ≥ 75 years old had the SARS-CoV-2 infection from March to May 2020. The incidence
rate of PE was estimated as the proportion of new cases within the whole sample. Youden’s index
was used to assess the cutoff point of D-dimer. To select factors associated with the risk of PE, time-
to-event analyses were performed using cause-specific hazard models. Results: In total, 305 patients
with a median age of 87 years (62.3% female) were studied; 67.9% were referred from nursing homes
and 90.4% received any type of anticoagulation. A total of 64.9% showed frailty and 44% presented
with dementia. The PE incidence was 5.6%. The cutoff value of a D-dimer level over 2.59 mg/L
showed a sensitivity of 82.4% and specificity of 73.8% in discriminating a PE diagnosis. In the
multivariate analysis, the factors associated with PE were previous oncological events and D-dimer
levels. Conclusions: The PE incidence was 5.6%, and major risk factors for PE were oncological
antecedents and increased plasma D-dimer levels.
Keywords: pulmonary embolism; older; COVID-19
1. Introduction
Acute respiratory distress syndrome is related to high mortality among coronavirus
disease 2019 (COVID-19) patients [1]. Recent observational studies have shown an increase
in embolic events, including pulmonary embolism (PE). The incidence has been estimated
to be 16 to 31% higher in critically ill patients than in those in a ward setting [2–4].
Elderly patients showed an increased prevalence of PE in the pre-COVID-19 era,
which is partly due to comorbidities associated with PE that increase exponentially with
age and are seven- to ten-fold more prevalent in patients of advanced aged than in younger
patients [5,6]. Thus, PE exhibits a different incidence based on age and race. The population
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in the fifth decade accounts for 200 per 100,000 people, and that over 80 years old increases
to 1134 per 100,000 [7–9]. The clinical features and outcomes of several cohorts have been
published; however, age plays a significant role in the outcomes of these patients, and the
data do not translate to older populations [10,11].
SARS-CoV-2 infection is related to coagulation impairment, with increased plasma
levels of procoagulants, such as fibrinogen and D-dimer, and an increased mortality
rate [12,13]. D-dimer is an accessible and reliable test for PE diagnosis, and its specificity
decreases as age increases. In the elderly population, increased plasma concentrations have
been proposed to rule out PE, thereby needing fewer diagnostic procedures [14]. D-dimer
concentrations over 1.0 mg/L have been identified to have an unfavorable prognosis [15,16].
A D-dimer cutoff of 5.0 µg/mL was determined to be an independent predictor of PE in
hospitalized COVID-19 patients [17].
PE risk in an elderly population severely affected by COVID-19 is not simply deter-
mined by the release of proinflammatory factors, such as IL-1 and Il-6, chemokines and the
thrombotic response [18]. Several factors, such as male sex, oncological entities, hypoxemia,
chronic obstructive pulmonary disease (COPD), pulmonary hypertension and heart failure
(HF), also influence the severity of this entity. HF is a major risk factor for embolic events.
Reduced mobility, venous stasis, blood viscosity and the proinflammatory state of HF
facilitate PE [19,20]
Our objective was to demonstrate the incidence and risk factors of PE in an elderly
cohort infected with SARS-CoV-2.
2. Material and Methods
2.1. Study Population
This ambispective, longitudinal, observational, cohort study was performed from
March to May 2020. This study is part of the OCTA-COVID-19 study. Patients aged
≥75 years who were admitted to the Geriatric Medicine Department with a COVID-19
diagnosis were recruited. Patients were included if they tested positive for SARS-CoV-2
by reverse transcription polymerase chain reaction from a combined oropharyngeal swab
with a clinical diagnosis of COVID-19. All clinical, laboratory and radiological data were
collected from the medical report.
2.2. Ethics Approvals
The protocol was approved by the ethics committee under ID: I-4131. This study
complied with the Declaration of Helsinki. All participants provided written informed
consent. Collected data were appropriately made anonymous, and each patient was
identified by a unique alphanumeric identification code.
2.3. Data Collection
The biodemographic data and clinical characteristics were collected at admission. The
clinical variables included the presence of high blood pressure, diabetes mellitus type 2,
atrial fibrillation (AF) and a history of congestive HF, PE, renal failure, COPD and cancer.
The Clinical Frailty Scale (CFS) [21] was used to assess frailty in the two weeks before
hospitalization. The degree of dependence was calculated using the Barthel Scale, [22] and
the presence of dementia was assessed by the Global Deterioration Scale (GDS) [23].
2.4. Laboratory Procedures
SARS-CoV-2 detection was performed using real-time reverse transcription poly-
merase chain reaction (RT-PCR) on nasal swabs. Routine blood examinations included
complete blood count, coagulation profile with D-dimer, serum biochemical tests (renal
and liver function, creatine kinase, lactate dehydrogenase and electrolytes), serum ferritin
and C-reactive protein (CRP). Chest radiographs were performed to assess the effects on
the lungs.
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2.5. Definitions
Patients were classified according to the clinical pretest probability as low, moderate
and high risk according to the Wells scale, and the D-dimer levels were adjusted to the age
of the patient, considering that the D-dimer level was elevated above 1 µg/mL. A positive
CT scan confirmed the presence of PE, defined by the absence or presence of filling defects
in one or more pulmonary arteries up to subsegmental arteries. Patients with a lower
renal filtration <30 mL/mL/min/1.73 m2 were excluded from the CT scan. In those with
filtration between 30–45 mL/min, a hydration protocol was carried out prior to the test.
Sepsis and septic shock were defined according to the 2016 Third International Con-
sensus Definition for Sepsis and Septic Shock [24]. The pneumonia severity of the mortality
scale CURB-65 was used, as recommended by the British Thoracic Society [25].
2.6. Outcomes
Our primary outcome was confirmed presence of PE. Secondary outcomes were
determining risk factors for PE in an older cohort infected with SARS-CoV-2.
2.7. Statistical Analysis
Continuous variables are summarized as the medians and interquartile ranges (IQR),
and categorical data are summarized as the frequencies and percentages. For univariate
comparisons, the Mann–Whitney U test was used because of the nonnormal distribution of
the continuous data. Categorical data were compared using the chi-square test or Fisher’s
test, according to the expected counts.
The incidence rate of PE was estimated as the proportion of new cases within the
whole sample, followed by 95% Wilson score confidence intervals.
The performance of the D-dimer level as a diagnostic predictor of PE was assessed.
The area under the receiver operating characteristic (ROC) curve and a cutoff value were
calculated using Youden’s index. Sensitivity, specificity, and predictive values and their
95% confidence limits were calculated.
To select factors associated with the risk of PE, time-to-event analyses were performed
using cause-specific hazard models to account for the occurrence of death as a competing
risk. Univariate analyses were carried out with selected variables according to the investi-
gators’ criteria. Finally, statistically significant variables in the univariate analyses were
included in a multivariate model.
All analyses were performed with SAS® 9.4 (SAS Institute Inc., Cary, NC, USA).
A p-value ≤ 0.05 was considered statistically significant.
3. Results
3.1. Participant Characteristics
In total, 305 patients (62.3% female) were included in this study (Table 1). The median
age was 87 years old (IQR 82–91). A significant difference in age was observed between
cohorts with and without PE involvement (p = 0.046). Detailed data regarding signs and
symptoms, blood and radiological results and treatment are included.
Regarding the geriatric characteristics of this cohort, 207 (67.9%) patients were referred
from a nursing home. A total of 205 (67.9%) subjects showed any kind of frailty or dementia
(44.4%). Dementia was classified into Alzheimer’s in 69 patients (23.2%), vascular dementia
in 23 (7.7%) and other types in 66 (22.1%). Of the patients with Alzheimer’s dementia,
17.4% had GDS4, 17.4% had GDS5, 44.9% had GDS6 and 15.9% had GDS7.
Regarding anticholinesterase treatment of all patients with Alzheimer’s dementia,
47.7% received some type of treatment. Forty-nine patients (16.1%) took some type of
antipsychotic, of which 36 patients (11.8%) received quetiapine and 13 (4.3%) received
risperidone.
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Table 1. Characteristics of the population of the study.
Global Population PE (n = 17) Non-PE (n = 288) p
Age (years), median 87 (82–91) 83 (80–86) 87 (82–91) 0.046
Sex (male) 115 (37.7) 9 (52.9) 106 (36.8) 0.182
Place of origin 0.805
Home 98 (32.1) 5 (29.4) 93 (32.3)
Nursing home 207 (67.9) 12 (70.6) 195 (67.7)
Days since COVID-19 symptom onset 5 (2–7) 5 (2–10) 5 (3–7) 0.892
Comorbidities
Arterial hypertension 204 (66.9) 9 (52.9) 195 (67.7) 0.209
Diabetes mellitus 86 (28.2) 5 (29.4) 81 (28.1) 1.000
Atrial fibrillation 85 (27.9) 4 (23.5) 81 (28.1) 0.788
COPD 48 (15.7) 3 (17.6) 45 (15.6) 0.737
Chronic renal dysfunction 53 (17.4) 0 (0) 53 (18.4) 0.051
Oncological history 41 (13.4) 6 (35.3) 35 (12.2) 0.016
Prior PE 18 (5.9) 1 (5.9) 17 (5.9) 1.000
Heart failure 74 (24.3) 2 (11.8) 72 (25.0) 0.380
Geriatrics assessment
Charlson Comorbidity Index 2 (1–4) 3 (1–5) 2 (1–4) 0.272
Barthel Index categories 65 (29–90) 75 (60–100) 64.5 (26–90) 0.061
CFS 205 (67.9) 6 (35.3) 199 (69.8) 0.003
Global deterioration scale 134 (44.4) 6 (35.3) 128 (44.9) 0.438
Chronic treatment
Angiotensin-converting enzyme inhibitors 150 (49.2) 9 (52.9) 141 (49.0) 0.750
Angiotensin receptor blockers 53 (17.4) 3 (17.6) 50 (17.4) 1.000
Oral antidiabetics 55 (18.0) 4 (23.5) 51 (17.7) 0.521
Oral anticoagulation 84 (27.5) 3 (17.6) 81 (28.1) 0.417
Beta-blockers 57 (18.7) 4 (23.5) 53 (18.4) 0.534
Digoxin 12 (3.9) 0 (0) 12 (4.2) 1.000
Antidepressants 111 (36.4) 6 (35.3) 105 (36.5) 0.923
Quetiapine 36 (11.8) 3 (17.6) 33 (11.5) 0.435
Symptoms at hospitalization
Cough 136 (44.7) 5 (29.4) 131 (45.6) 0.191
Fever 156 (51.1) 8 (47.1) 148 (51.4) 0.729
Dyspnea 179 (58.7) 12 (70.6) 167 (58.0) 0.305
Falls 33 (10.8) 4 (23.5) 29 (10.1) 0.098
Delirium 112 (36.7) 5 (29.4) 107 (37.2) 0.520
Clinical signs
Fever 36.9 (36.3–37.8) 37.05 (36.6–38.15) 36.9 (36.3–37.8) 0.400
Blood oxygen saturation (%) 92 (88–95) 92 (88–94) 93 (88–95) 0.285
Blood pressure (mmHg) 129 (110–147) 124 (110–138) 129 (110–148) 0.334
Respiratory rate (breaths/min) 20 (18–28) 21 (18–28) 20 (18–28) 0.793
Heart rate (beats/min) 84 (72–97) 95 (85–106) 83 (72–96) 0.007
CURB-65 2 (1–3) 2 (1–3) 2 (1–3) 0.518
SOFA 1 (0–1) 0 (0–1) 1 (0–1) 0.111
Blood test
Platelets, median (103/µL) 230 (167–324) 229 (208–248) 230 (164–329) 0.710
Leukocytes 7620 (5570–9970) 7200 (5920–8880) 7640 (5565–10,180) 0.483
Lymphocytes (103/µL) 0.89 (0.6–1.25) 0.82 (0.47–1.1) 0.9 (0.61–1.27) 0.421
CRP mg/L 65 (26.9–151) 49 (21–158) 66.4 (27–149) 0.783
Creatinine (mg/dL) 0.97 (0.7–1.4) 1 (0.63–1.3) 0.97 (0.7–1.4) 0.739
Ferritin (ng/dL) 267 (156–469.5) 212 (178 – 586) 278 (156 – 467) 0.905
Peak D-dimer (mg/L) 1.66 (0.89–3.16) 6.14 (2.94–8.71) 1.58 (0.86–2.93) <0.001
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Table 1. Cont.
Global Population PE (n = 17) Non-PE (n = 288) p
Radiology
Pneumonia 250 (82.0) 11 (64.7) 239 (83.0) 0.095
Pneumonia type 0.227
Unilateral 25 (8.2) 0 (0) 25 (8.7)
Bilateral 60 (19.7) 2 (11.8) 58 (20.1)
Multilobar 165 (54.1) 9 (52.9) 156 (54.2)
Medication
Hydroxychloroquine 264 (86.6) 13 (76.5) 251 (87.2) 0.261
Azithromycin 191 (63.0) 11 (64.7) 180 (62.9) 0.883
Lopinavir 22 (7.2) 2 (11.8) 20 (6.9) 0.351
Steroids 111 (37.1) 7 (41.2) 104 (36.9) 0.722
Hospitalization
Length of in-hospital stay (days) 11 (6–18) 24 (13–30) 11 (6–17) <0.001
Discharge 193 (63.3) 14 (82.4) 179 (62.2) 0.093
Death, n (%) 112 (36.7) 3 (17.6) 109 (37.8) 0.093
CFS—Clinical Frailty Scale; COPD—chronic obstructive pulmonary disease; CURB-65—severity score for predicting mortality from
community-acquired pneumonia. PE—pulmonary embolism; CRP—C-reactive protein; SOFA—Sequential Organ Failure Assessment.
Data are presented as the medians and interquartile ranges or numbers (%).
The mean Charlson Comorbidity Index score was 2 (IQR 1–4), while the mean Barthel
Index score was 65, which is compatible with a moderate degree of dependence. Among
the geriatric syndromes, only frailty was highlighted; 35.3% of patients included in the PE
cohort showed frailty compared to 69.8% in the non-PE cohort (p = 0.003).
Only previous oncological antecedents were significantly different between the groups
(p = 0.0016). The median D-dimer level was higher in the PE group than in the non-PE
group. However, the CRP level and ferritine level showed no differences between the
groups. The mean hospitalization time in the PE cohort was longer than that in the non-PE
group (24 days, (IQR 13–30) vs. 11 days, (IQR 6–17) (p = < 0.001)).
3.2. Incidence of Pulmonary Embolism
The presence of PE was observed in 17 of 305 patients, with an incidence of 5.6% (95%
CI: 3.5% to 8.7%) diagnosed by positive computed tomography pulmonary angiography
(CTPA). Fifteen patients (4.9%) had an isolated PE event, two patients (0.7%) were diag-
nosed with both PE and deep vein thrombosis and three patients (1%) had only deep vein
thrombosis.
3.3. Sensitivity and Specificity of D-Dimer Measurement in the Geriatric Population with PE
We sought to identify the plasma D-dimer concentration value that could be consid-
ered a good and reliable discrimination marker of PE in our elderly population. The area
under the curve (AUC) was lower than 0.799 (0.699–0.899) for a cutoff value of D-dimer
concentration equal to or higher than 2.59 mg/L in patients over 70 years old (Figure 1).
We also classified patients according to whether their D-dimer was above the adjusted
D-dimer level (that is, age divided by 100 mg/L units). Regarding this adjusted D-dimer,
the results were: Sensitivity 100% (81.6–100), Specificity 22.9% (18.4–28.1), PPV 7.1%
(4.5–11.1), 100% NPV (94.5–100).
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3.4. Risk Factors Related to PE in Patients Affected by COVID-19
The variables associated with PE and mortality in the univariate analysis were age,
previous oncological history, frailty, tachycardia and D-dimer level. Using hazard models,
previous oncological events were a strong independent predictor of PE (HR 3.17; 95%
CI 1.15–8.74) (p = 0.026)), followed by the D-dimer level (HR 1.02; 95% CI 0.999–1.049)
(p = 0.062)). Nevertheless, frailty showed a protective effect, meaning that fewer patients
with frailty showed PE (HR 0.34; 95% CI 0.999–1.049) (p = 0.054)) (Table 2).





Age (years) 0.93 (0.87–0.99) 0.025
Age ≥ 85 0.33 (0.12–0.89) 0.029 0.46 (0.15–1.39) 0.167
Diabetes mellitus 0.92 (0.34–2.52) 0.874
Oncological history 3.44 (1.32–9.01) 0.012 3.17 (1.15–8.74) 0.026
Heart failure 0.37 (0.08–1.66) 0.194
Prior PE 1.14 (0.16–8.14) 0.898
Deep venous thrombosis 0.73 (0.11–4.93) 0.745
Falls 2.29 (0.78–6.72) 0.131
Dementia 0.66 (0.25–1.76) 0.403
Acetylcholinesterase Inhibitors 2.94 (0.93–9.28 0.067
Antipsychotic drugs 1.11 (0.31–3.96) 0.876
Frailty 0.23 (0.09–0.60) 0.003 0.34 (0.11–1.02) 0.054
Dependence 0.24 (0.09–0.63) 0.004
Dyspnea 1.55 (0.55–4.34) 0.408
Respiratory rate (breaths/min) 1.00 (0.94–1.06) 0.961
Tachycardia 1.02 (1.01–1.04) 0.001
CRP mL/L 1.00 (0.994 – 1.004) 0.724
Ferritine (ng/mL) 1.00 (0.999 – 1.001) 0.743
D-dimer 1.03 (1.004–1.048) 0.020 1.02 (0.999–1.049) 0.062
D-dimer ≥ (2.59 mg/L) 10.06 (2.90–34.92) <0.001
PE—pulmonary embolism; HF—heart failure; CRP—C-reactive protein; HR—hazard rate, CI—confidence interval.
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4. Discussion
Key Findings
PE is a dynamic process that shares common features with HF and COPD and makes
the diagnosis complex. Thus, PE is over- and underdiagnosed. In the early stages of the
pandemic, dyspnea, dementia, delirium and the excessive increase in D-dimer levels in
the elderly population affected by COVID-19 led to confusion in the early diagnosis of
PE, evolving therapeutic management from the adaptation stage to the arduous stage. To
our knowledge, this is the oldest cohort affected by COVID-19. We studied 305 patients
hospitalized in a secondary geriatric hospital with a PE incidence of 17/305 patients, which
represents an incidence of 5.6% (95% CI: 3.5% to 8.7%). This incidence is higher than
that reported by Lodiagini et al. [3] with 10/362 patients (2.8%) or Benito et al. [26], who
described an incidence of 2.6% PE in 1275 inpatients who underwent CTPA. This could be
explained by the scarcity of CTPA performed in the latter population, underestimating the
true figure of affected patients.
The Prophylaxis in Medical Patients with Enoxaparin (MEDENOX) trial, which was
performed in the pre-COVID-19 era on a population with acute medical illness with mod-
erate risk of a thromboembolic event [27], set the embolic event reduction and beneficial
anticoagulant prophylaxis for acute disease cohorts. Although most of the hospitalized
patients with COVID-19 were on anticoagulant therapy, the incidence of PE was high.
SARS-CoV-2 infection promotes endothelial dysfunction, prothrombotic events and pul-
monary microthrombi, and the inflammatory host response leading to PE has been proven
in autopsy studies [28]. Poissy et al. [29] showed that patients with COVID-19 infection had
a higher frequency of PE than patients affected with other infections. They also proposed a
pulmonary thrombosis mechanism rather than embolism due to the low diagnostic deep
vein thromboses found.
The D-dimer level was increased in the PE cohort. This increased D-dimer concen-
tration mirrors SARS-CoV-2 and acute lung injury, decreasing the PaO2/FiO2 ratio (PAFI)
and driving coagulation activation secondary to the inflammatory response.
This threshold of the D-dimer concentration, 2.59 mg/L, is similar to that reported in
other works. Leonard-Lorant et al. [30] established a cutoff point of 2.66 mg/L, allowing
the detection of PE in all patients for whom CTPA was performed. On the other hand, Cui
et al. [31] used a lower plasma level of D-dimer as a predictor of embolic events. They
proposed increasing the threshold to 3 mg/L to detect the high-risk group for pulmonary
events; this cutoff value improved the specificity to 94.9% and the negative predictive
value to 92.5%. Unlike the aforementioned authors, our study population consisted of
older adults, many of whom had frailty, some degree of dependence and other pathologies
that may mask symptoms, leading to underprescription of the diagnostic test and possible
misdiagnosis of PE. Thus, we propose this cutoff value for the D-dimer concentration in
this population to support the detection of embolic events in elderly patients infected with
SARS-CoV-2.
Several predictive factors of PE in elderly patients affected by COVID-19 have been de-
scribed, such as unit care admission, the time of hospitalization and D-dimer levels [32,33].
We confirmed, according to Al-Samkari et al. [34], that a D-dimer level of 1.0 to 2.5 mg/L
had an odds ratio (OR) for thrombotic complications of 3.04. In this sense, a plasma D-dimer
plasma concentration over 1 µg/mL was associated with a risk of PE. Benito et al. [26]
proposed that levels of CRP over 150 mg/dL and D-dimer over 1 mg/L could identify
patients at risk for PE, who therefore could be candidates for increased thromboprophylaxis
doses. CTPA should be performed when the D-dimer level persistently increases.
The predictive factors for PE found in our study help identify patients who will benefit
from an early diagnosis of PE. This cohort is more vulnerable to several comorbidities
and a longer in-hospital stay. According to a French multicenter cohort study, our mean
in-hospital length of stay increased significantly in the PE group, from 11 to 24 days [35].
The wide clinical spectrum of PE related to oncological events has been established
as an important predictor of PE in our population. Before the COVID-19 era, these data
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were confirmed, showing a four- to seven-fold increase in thrombotic complications in
oncological patients compared with those in the general population [36]. Thus, the presence
of oncological history was an independent mortality factor for elderly patients with PE
events six months after hospital discharge [37]. Surprisingly, a traditional risk factor for
PE as an oncological event has not been assessed in different COVID-19 patients [19,38].
Cancer was present in 18% of RIETE registry [39] patients over 80 years old with venous
thrombosis, which was similar to the percentage of younger patients but higher than that
observed in other COVID-19 series where the mean age was 65 years old [3,11]. This high
oncological prevalence and its relation to thrombotic events could help identify patients at
risk.
Al Ghatrif et al. [40] demonstrated that age could influence COVID-19 infection.
Older patients have shown a reduced concentration of angiotensin-converting enzyme-2;
moreover, oxidative stress and the inflammatory response have an increased intensity and
could also be promoted by tumor progression.
Our results confirm that, within the senior population, there are different outcomes
in younger patients than in the group over 85 years old. Patients younger than 85 years
old with reduced frailty showed an increased risk of PE. Our study demonstrates an
increased prevalence of frailty (67%) in patients admitted to the hospital due to COVID-19
compared to other series reported in the multicenter COVID-19 in Older People (COPE)
study [41]. Our population was recruited from a geriatric hospital, and an increased
number of participants came from nursing homes. To our knowledge, no study has
related frailty to embolic events. The most interesting results in our cohort are that the
less frail group showed more PE, confirming the association between inflammation and
thrombosis [42]. This study reported that low-to-moderate fragility was associated with
higher inflammatory markers than severe and very severe frailty. The inflammatory
response is the basis of the defense against external and internal injuries [43]. In the young
population, this response is needed against infectious diseases. The context is different in
90- and 100–year-old patients who may have retarded inflammatory biomarkers that delay
age-related diseases and protect against the adverse effects of maintaining the response.
In this context, immunosenescence could influence the response of the immune system
to an acute infection, such as COVID-19. This response could limit the cytokine storm in
geriatric patients and slow the prothrombotic and inflammatory cascades [44,45].
Although immunosenescence phenomena have gained interest in recent years, their
molecular mechanisms have not been completely studied. Due to the drastic increase in the
global life expectancy, more in-depth studies are required to identify and understand how
aging influences the immune system. The clinical implications of these findings remain
to be explored in larger studies with longitudinal follow-up. Furthermore, it would be
valuable to compare patients with COVID-19 to patients who have experienced other viral
infections.
5. Conclusions
The difficulty in the early diagnosis of PE in older patients infected by COVID-19
represents a challenge in the in-hospital management of these patients. The findings
of this study can help understand the population at risk of developing PE and avoid
unnecessary testing. The incidence of PE in the geriatric population tested by CTPA was
5.6%. Cancer and D-dimer concentrations were independent factors associated with PE in
this population. The D-dimer cutoff value of 2.59 mg/L appears to be a good discriminator
of PE, with a sensitivity of 82.4% and specificity of 73.8% for detecting new cases.
6. Limitations
This study has several limitations. First, due to the intrinsic characteristics of the
pandemic and the high workload, there was a relatively short time to collect data during
patient hospitalization. Second, there was a restriction on accessing different diagnostic
tests and complex logistics to confirm PE, such as CTPA, the gold standard test. Third,
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the severity in our cohort at the very beginning of the pandemic could have influenced
the diagnosis of PE. Finally, variables for the analysis were collected at admission; there
was a lack of follow-up and the dynamic influence of COVID-19 disease evolution was not
considered.
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